79 results about "Virulence factor" patented technology

The invention discloses a lytic bacteriophage for preventing and controlling vibrio in an aquaculture environment. The bacteriophage vBValMR42H belongs to a muscle tail bacteriophage and is insensitive to chloroform, the capsid of the bacteriophage vBValMR42H is free of lipid substances, and the preservation number is GDMCC No: 67434-B1. The bacteriophage has the characteristics of high adsorption speed, short incubation period and high cracking amount, keeps high activity in a wide range of temperature (4-55 DEG C) and pH (2-11), and has strong environmental adaptability. Genome analysis shows that the bacteriophage does not contain virulence factors, antibiotic resistance genes and lyogen related genes, and is high in biological safety. Physical development analysis shows that the method can be divided into a new genus. The bacteriophage R42H has the advantages of high splitting efficiency, good environmental stability, strong specificity, gene safety and the like, and can be used as an ideal biological prevention and control agent for preventing and controlling vibrio alginolyticus diseases in aquaculture.

The invention discloses a novel aeromonas salmonicida virulence comparison method based on image analysis, and the method comprises the steps: obtaining aeromonas salmonicida samples from different sources, carrying out image collection, and obtaining the image data of aeromonas salmonicida; carrying out preprocessing and Canny edge detection on the collected image data, segmenting a microorganism image, and extracting a target microorganism region; extracting characteristics related to the toxicity of aeromonas salmonicida from the segmented image through an image analysis technology; the extracted features are compared with a known aeromonas salmonicida virulence factor database, and the virulence strength of the thalli to be detected is evaluated; and arranging and summarizing data generated in a comparison process, and outputting a comparison and evaluation result in a visual form. According to the method disclosed by the invention, the virulence characteristics of aeromonas salmonicida from different sources or under different conditions can be quickly and accurately compared, and the difference between strains can be more intuitively reflected, so that the accuracy and efficiency of virulence comparison are improved.

Provided herein are vaccine compositions for preventing and combating infection by Shigella. In particular, the present disclosure provides a composition comprising a Shigella virulence factor VirG (or IcsA) protein or a fragment thereof comprising about 100-400 amino acids of the VirG protein having an amino acid sequence that is at least 90% identical to the sequence set forth in SEQ ID NO: 2.

The invention discloses application of lvpA-NF-kappa B p65 interaction in pathogenicity evaluation of staphylococcus lugdungensis. The invention reveals that a staphylococcus lugdungensis virulence factor lvpA can be directly and specifically combined with a key protein p65 of a host NF-kappa B signal channel for the first time. The invention provides an in-vitro detection kit for a non-diagnostic purpose. The in-vitro detection kit comprises a reagent capable of capturing or marking lvpA protein and p65 protein. Meanwhile, the invention discloses application of the lvpA protein or the functional fragment of the lvpA protein in preparation of a reagent or a kit for evaluating potential pathogenicity of a strain in vitro or screening candidate substances interfering the interaction, and application of polypeptide capable of competitively inhibiting the interaction in preparation of an in-vitro reagent. The invention provides a new perspective for the research on the pathogenic mechanism of staphylococcus lugdunensis infection, and provides a new target spot and means for developing related detection tools and anti-toxicity strategies.

The invention relates to application of raloxifene hydrochloride in preparation of a population effect inhibitor. The invention verifies that the raloxifene hydrochloride can inhibit the population effect of bacteria through a violaceum violaceum luminescence method, and further proves that the raloxifene hydrochloride can inhibit the population effect of pseudomonas aeruginosa and the generation of virulence factors through the inhibition of biological back membrane formation and the inhibition effect of virulence factor generation. The compound is expected to be developed into a clinically available group effect inhibitor, and has an important research value for solving the problems of bacterial infection and drug resistance.

The present application belongs to the technical field of quorum quenching enzyme preparation, and particularly relates to a multi-target quorum quenching enzyme preparation and a preparation method and application thereof, such as being mainly used for inhibiting the virulence factors of Pseudomonas aeruginosa, and including acyl homoserine lactone acyltransferase AiiO protein and 3-hydroxy-4-oxoquinolone 2,4-dioxygenase AqdC protein, and the mass ratio of the two is 20:(1-25); such as being mainly used for inhibiting the virulence factors and the synthesis of biological membranes of Pseudomonas aeruginosa, and further including deferiprone, and the mass ratio of AiiO, AqdC and deferiprone is 20:(1-25):(0.695-2.78), the present application can target the Las, Rhl and PQS of Pseudomonas aeruginosa, the yield and stability of the prepared AqdC protein are both high, the two types of enzymes are used in combination after the regulation amount, and the virulence factors regulated by different quorum sensing pathways in Pseudomonas aeruginosa are effectively inhibited; the regulation amount of deferiprone is used in combination with the two types of quorum quenching enzymes, and the virulence and biological membranes of Pseudomonas aeruginosa can be effectively inhibited in a comprehensive manner.

The application provides a hot liquid source quorum quenching strain Shiquan Haeyuan bacteria and application thereof, the strain screened can inhibit pathogenic bacteria and is used for preparing bacteriostatic drugs; the preservation number of the Shiquan Haeyuan bacteria screened is CCTCC NO: M 20251224.The application also provides an AHL degradation enzyme Aii937 protein separated from the YESM3 strain, characterized in that the amino acid sequence of the protein is SEQ ID NO: 2.The YESM3 strain of the application can block the QS path of pathogenic bacteria through AHL lactonase Aii937, reduce the secretion of virulence factors of pathogenic bacteria; the strain YESM3 has no pathogenicity.AHL lactonase does not have broad spectrum, has strong substrate specificity, and only degrades C6-HSL and 3OC-C 14 -HSL.

The invention relates to the technical field of probiotics, in particular to swine-derived probiotic escherichia coli CP57 (Escherichia coli CP57) as well as a preparation method and application of the swine-derived probiotic escherichia coli CP57. The strain is separated from feces of healthy piglets, has good acid resistance and cholate resistance, does not carry virulence factors of common diarrhetic escherichia coli, does not have obvious cytotoxicity and has good safety. The strain can significantly inhibit the growth of salmonella, can relieve clinical symptoms caused by salmonella infection in a salmonella infected mouse model, and reduces the content of salmonella in mouse feces and in vivo. The Escherichia coli CP57 provided by the invention has the potential of preventing and controlling enteropathogenic bacteria infection of livestock, can be used for preparing a microecological preparation for preventing and controlling intestinal infection of livestock, and has important application value.

This invention discloses the application of 6-methyladenine in the preparation of drugs against Pseudomonas aeruginosa infection. This invention provides the application of 6-methyladenine in the preparation of drugs against Pseudomonas aeruginosa (… Pseudomonas aeruginosa Application in infectious agents. The 6-methyladenine described in this invention inhibits the quorum sensing of Pseudomonas aeruginosa and the production of related virulence factors, thereby suppressing Pseudomonas aeruginosa infection in vivo and in vitro, reducing host mortality, and providing a new therapeutic strategy for the prevention and control of Pseudomonas aeruginosa infection.

The invention relates to an application of pimozide in preparation of a population effect inhibitor. The invention verifies that pimozide can inhibit the population effect of bacteria through a violaceum violaceum luminescence method, and further proves that pimozide can inhibit the population effect of pseudomonas aeruginosa and the generation of virulence factors through the inhibition of biological back membrane formation and the inhibition effect of virulence factor generation. The compound is expected to be developed into a clinically available group effect inhibitor, and has an important research value for solving the problems of bacterial infection and drug resistance.

The application discloses an ebselen derivative, a pharmaceutical composition and application thereof. The ebselen derivative has a structure as shown in formula (I) or formula (II). The ebselen derivative provided by the application has the characteristics of inhibiting PPK activity, reducing the polyP level of bacteria, reducing the formation of a biofilm, reducing the movement ability of bacteria, reducing the generation of a virulence factor, and enhancing the sensitivity of bacteria to antibiotics, and thus can be used for preventing and treating bacterial infectious diseases.

The present application relates to the technical field of biology, and particularly relates to a bacteriophage vB_SalP_SE29, a bacteriophage vB_SalP_SE29 preparation and application thereof.The present application provides the bacteriophage vB_SalP_SE29, and the preservation number of the bacteriophage vB_SalP_SE29 is CGMCC No.46499.The present application provides a chicken salmonella pullorum bacteriophage, and through whole genome sequencing analysis, no gene sequence related to lysogeny conversion, antibiotic resistance and virulence factor is detected in the genome of the bacteriophage, so that the biological safety of the bacteriophage for drug development and bactericidal product research is ensured from a molecular level, and potential biological risks are effectively avoided.

This application relates to a label-free immunosensor for Helicobacter pylori, its preparation method, and its application. The method involves directly incubating the Helicobacter pylori multivalent epitope antigen FvpE on a modified electrode, eliminating the need for hybridization labeling during the preparation of the label-free immunosensor. This simplifies the preparation process, making it simple and easy to operate. Furthermore, the prepared label-free immunosensor can directly detect Helicobacter pylori in samples, greatly simplifying the detection process and reducing detection time. Simultaneously, the prepared label-free immunosensor can detect polyclonal antibodies anti-Hp and different antibody genotypes such as CagA, UreA, UreB, and VacA, and can simultaneously detect multiple cytotoxins or virulence factors. This improves the universality of the label-free immunosensor, thereby reducing workload, shortening detection time, and lowering detection costs.

The invention discloses a bacteriophage vBValPR44J with the potential of preventing and controlling vibrio diseases. The preservation number of the vibrio alginolyticus bacteriophage vBValPR44J is GDMCC No: 67435-B1, and the preservation number of the vibrio alginolyticus bacteriophage The vBValPR44J belongs to schizoviridae, but has extremely low similarity with a genome of a known related strain, and represents a new candidate virus genus. A one-step growth curve reveals that the R44J has an extremely short incubation period and efficient host lysis activity. In addition, genomic safety assessment proves that R44J does not carry any lyogen-related genes, virulence factors or antibiotic resistance-related genes. In conclusion, due to the unique taxonomic status, efficient splitting capacity and excellent genetic safety of the R44J, the R44J has a wide application prospect as a biological agent for preventing and controlling the aquaculture vibriosis.

The invention discloses a lactic acid bacteria composition, lactic acid bacteria fermentation liquor, a lactic acid bacteria agent, fermented milk and a preparation method and application thereof, and belongs to the technical field of microorganisms. The lactobacillus composition disclosed by the invention is prepared from lactobacillus johnsonii S2L, lactobacillus reuteri S5L and lactobacillus mucous membrane mucus S16L; the preservation number of the lactobacillus johnsonii S2L is GDMCC No: 66569; the preservation number of the lactobacillus reuteri S5L is GDMCC No: 66558; the preservation number of the lactobacillus mucous membrane S16L is GDMCC No: 66559. The strains in the lactic acid bacteria composition have excellent probiotic characteristics, do not have virulence factors, are fermented in the milk replacer, are short in fermentation time, can improve the protein hydrolysis degree of the milk replacer, reduce the incidence rate of lamb diarrhea and optimize the intestinal microflora, and have positive effects on improving the feed intake of lambs.

This application relates to a species of Pseudomonas aeruginosa. bpsR Genes, BpsR proteins and their applications, engineered bacteria, and drugs, among which bpsR The nucleotide sequence of the gene is shown in SEQ ID No. 1. This invention... bpsR Genes, through regulation in Pseudomonas aeruginosa bpsR Gene expression can regulate the virulence factors of Pseudomonas aeruginosa, such as biofilm production, pyocyanin production, motility, and elastase secretion levels. Furthermore, BpsR protein can be used as a new target for the development of drugs to prevent and treat Pseudomonas aeruginosa, which has important clinical significance for the prevention and control of Pseudomonas aeruginosa infection.

The invention relates to application of silodosin in preparation of a population effect inhibitor. The invention verifies that silodosin can inhibit the population effect of bacteria through a violaceum violaceum luminescence method, and further proves that silodosin can inhibit the population effect of pseudomonas aeruginosa and the generation of virulence factors through the inhibition of biological back membrane formation and the inhibition effect of virulence factor generation. The compound is expected to be developed into a clinically available group effect inhibitor, and has an important research value for solving the problems of bacterial infection and drug resistance.

The invention belongs to the technical field of genetic engineering, and particularly relates to recombinant lactobacillus plantarum for preventing and controlling chicken necrotic enteritis as well as a preparation method and application of the recombinant lactobacillus plantarum. The invention provides an oral vaccine vector capable of co-expressing various key virulence factor antigens (FimB, NetB, CnaA and FBA) of clostridium perfringens, and by fusing dendritic cell (DC) targeting molecules (nano antibody Phi74), the efficiency of recognizing and taking in the vaccine vector by full-time antigen presenting cells is remarkably improved, so that the immunogenicity is enhanced. When the recombinant lactobacillus is used for immunizing animals, mucosal immunity, cellular immunity and humoral immunity reactions can be induced, the immunity of organisms is comprehensively enhanced, and a safe and efficient oral immunization scheme suitable for large-scale breeding is established for treating chicken necrotic enteritis.

This invention discloses a strain of *Bacillus belyceae* with broad-spectrum antibacterial activity and its application in the prevention and treatment of necrotic enteritis in poultry. The *Bacillus belyceae* strain provided by this invention (… Bacillus from Velez The genome of strain GDG25CB056 is approximately 3.91 Mb in size, contains no virulence factors, and is rich in gene clusters encoding non-ribosomal peptides and polyketide synthases. Studies have confirmed that this strain exhibits significant growth advantages, strong tolerance to high temperatures, gastric acid, and bile salts, which facilitates intestinal colonization. It can produce siderophores and various enzymes, and has overcome the technical bottleneck of a narrow antibacterial spectrum, possessing broad-spectrum antibacterial activity, especially strong specific antagonistic activity against Clostridium perfringens. In vivo experiments have shown that this strain can significantly reduce the Clostridium perfringens load in the cecum of chicks with necrotizing enterocolitis, alleviate intestinal congestion and swelling, repair damaged intestinal villi, and enhance mucosal barrier function, providing a safe and efficient strain resource for the prevention and treatment of bacterial enteric diseases.

To provide a method for Bordetella fermentation and virulence factor production, especially PT production, for large-scale production, and in particular, to provide a method for medium adaptation performed before inoculation.SOLUTION: A method of producing a conditioned growth media comprising the steps of a. providing a sterile growth media; b. holding the sterile growth media at a temperature between about 28 to about 35 °C. for about 20 to 35 hours; and c. agitating and / or aerating the sterile growth media to generate a volumetric oxygen transfer coefficient (kLa) of about 10h-1 to about 130h-1, thereby providing a conditioned growth media.SELECTED DRAWING: Figure 1

The invention discloses application of morin, and relates to the technical field of bacterial quorum sensing inhibition. The invention discloses application of morin in preparation of a medicine for reducing enterotoxigenic escherichia coli quorum sensing. Quorum sensing of enterotoxigenic escherichia coli can be reduced by using 5.0 mg / mL of Morrin, so that secretion of virulence factors of the enterotoxigenic escherichia coli is reduced. In the Escherichia coli treated by the Morin, the Morin has no obvious inhibition effect on the growth of the Escherichia coli, and the abundance of an autoinducer 2 (AI-2) and a quorum sensing related gene is obviously reduced, so that the toxicity and the adhesion capability of the Escherichia coli are reduced. The method for reducing enterotoxigenic Escherichia coli quorum sensing provided by the invention is beneficial to replacing traditional antibiotic in-vivo treatment and assists in resisting bacterial infection.

This invention provides a recombinant Staphylococcus aureus nanoparticle protein HI-mi3, its preparation method, and its applications. This protein is composed of HI (containing the key SA virulence factor α-hemolysin Hla). H35L The fusion protein HI and mi3 are composed of the N2 functional domain of the iron ion surface determinant B and self-assembled nanoparticle protein mi3. This invention uses the SpyTag / SpyCatCher protein coupling system to link the fusion protein antigen HI and mi3, obtaining the Staphylococcus aureus self-assembled nanoparticle protein HI-mi3. Both the recombinant protein SpyCatcher-mi3 and the recombinant protein SpyTag-HI of this invention are induced to be expressed in soluble form in Escherichia coli. The recombinant protein SpyCatcher-mi3 of this invention can covalently bind to the recombinant protein SpyTag-HI via isopeptide bonds to form the HI-mi3 nanoparticle vaccine molecule, with simple binding conditions. The HI-mi3 nanoparticle vaccine of this invention can induce a high level of immune response in animals and exert an immunoprotective effect.

The invention provides a method for identifying, quantifying and visualizing genomes of drug-resistant pathogenic bacteria in environmental samples, which is suitable for identifying dangerous drug-resistant pathogenic bacteria in various environments. The method comprises the following steps: (1) based on a metagenome sequencing big data set, obtaining a high-quality bacterial genome by using genome quality control, assembly and binning technologies; (2) identifying a drug-resistant bacterium genome carrying an antibiotic drug-resistant gene, further annotating a virulence factor, and comparing with an authoritative pathogenic bacterium directory to realize accurate identification of drug-resistant pathogenic bacteria; and (3) mapping the reference genome of the drug-resistant pathogenic bacteria through the metagenome so as to quantify the abundance of the drug-resistant pathogenic bacteria, and further carrying out visual analysis on the drug-resistant pathogenic bacteria mediated drug-resistant genes, related movable genetic elements and other gene neighborhood structures. The method does not depend on isolated culture, realizes full-spectrum analysis of drug-resistant pathogenic bacteria in environmental samples, and provides important technical support for accurate and scientific evaluation of drug resistance risks of environmental bacteria antibiotics.

The present application relates to the technical field of pharmacy, in particular to application of compound Diaporterpene C in preparation of mycobacterium tuberculosis tyrosine phosphatase inhibitor. The present application provides application of compound Diaporterpene C in preparation of mycobacterium tuberculosis tyrosine phosphatase inhibitor, the compound can significantly inhibit the activity of key virulence factor tyrosine phosphatase MptpA and MptpB of mycobacterium tuberculosis, can be used as tyrosine phosphatase inhibitor with MptpA and / or MptpB as target, and can be further developed as anti-tuberculosis drug. The compound shows good anti-tuberculosis activity by inhibiting pathogenic signal pathway of pathogenic bacteria, and has important clinical application potential and development value in tuberculosis treatment.

A cell-penetrating polypeptide (CPP), which includes an amino acid sequence that is derived from, or is, a portion of a virulence factor, as well as a complex including the CPP, a polynucleotide encoding the CPP or complex, an expression vector encoding the CPP or complex, and a cell including the same. Also, methods for directing or delivering a molecule of interest into cells using the CPP, and to the use of the CPP for preventing or treating a disease.

The invention discloses an application of 3-indolepropionic acid in preparation of a medicine for inhibiting generation of a virulence factor of pseudomonas aeruginosa. According to the 3-indolepropionic acid, quorum sensing of pseudomonas aeruginosa and generation of related virulence factors of the pseudomonas aeruginosa are inhibited, so that in-vivo and in-vitro infection of the pseudomonas aeruginosa is inhibited, the death rate of a host is reduced, and a new treatment strategy is provided for prevention and control of infection of the pseudomonas aeruginosa.

This invention belongs to the field of medical pharmaceutical technology, specifically the application of midostaurin in the preparation of drugs that inhibit or combat Listeria monocytogenes. This invention provides a novel medical use of midostaurin, a drug for treating FLT3 mutation-positive acute myeloid leukemia (AML) and invasive systemic mastocytosis, in the prevention or treatment of Listeria monocytogenes infection. By targeting the key virulence factor PlcA in Listeria monocytogenes, it reduces phagocytic escape and proliferation within bacterial cells, thereby decreasing bacterial pathogenicity. In in vitro and in vivo therapeutic trials, midostaurin demonstrated significant therapeutic effects against Listeria monocytogenes infection, indicating broad medical applications.

This application relates to a species of Pseudomonas aeruginosa. bspZ Gene, BspZ protein Its applications, biomaterials, and drugs, among which bspZ The nucleotide sequence of the gene is shown in SEQ ID No. 1. This invention... bspZ Genes, through regulation in Pseudomonas aeruginosa bspZ Gene expression can regulate virulence factors of *Pseudomonas aeruginosa*, such as biofilm production, pyocyanin production, and motility. Furthermore, it can... BspZ protein As a new target for the development of drugs to prevent and treat Pseudomonas aeruginosa, it is of great significance for the prevention and control of Pseudomonas aeruginosa infection.

The invention specifically discloses a risk biomarker for cryptococcus meningitis and application thereof, and relates to the technical field of biological medicines. The invention provides a brand new cryptococcus brain infection antivirulence factor mitochondrial citric acid transporter: by closing the mitochondrial citric acid transporter, glucose metabolism hijacking in the brain is realized, and the colonization advantage is obtained.

The invention provides a novel application of a macleaya cordata extract as a salmonella type III secretion system (T3SS) inhibitor. Through construction of a chick infection model and in-vitro experiments, the extract is proved to be capable of remarkably reducing the bacterial load of infected chick liver and spleen tissues, relieving tissue pathological damage and reducing inflammatory cell infiltration. Mechanism research shows that the macleaya cordata extract can down-regulate the expression of T3SS key virulence protein SipA in a dose-dependent manner, interfere the function of a secretion system, and further block the secretion and expression of virulence factors. The invention discloses the potential application of the macleaya cordata extract in the aspect of resisting salmonella toxicity for the first time, and provides a development strategy and a technical basis of a T3SS inhibitor from a natural product.